#apixaban
LightNews LightNews
paulhoward.bsky.social
This "real world" study in pancreatic cancer related VTE reported in a JCO meeting abstract found apixaban was associated with less bleeding, fewer strokes and lower overall mortality compared to rivaroxaban

ascopubs.org/doi/abs/10.1...
Real-world effectiveness and safety of apixaban versus rivaroxaban in pancreatic cancer–associated VTE.
739Background: Pancreatic cancer is highly associated with venous thromboembolism (VTE), requiring long-term anticoagulation. However, evidence comparing outcomes between apixaban and rivaroxaban in t...
ascopubs.org
January 15, 2026 at 4:48 PM
med-iqcardiology.bsky.social
17/What other clinical trials for FXI/XIa inhibitors are in progress?
Ongoing phase 3 trials include the following studies for abelacimab: LILAC-TIMI 76 comparing abelacimab versus placebo in AF not eligible for OAC; ASTER comparing abelacimab versus apixaban for cancer-associated VTE; MAGNOLIA comparing abelacimab versus LMWH for GI cancer-associated VTE. The following studies for milvexian are ongoing: LIBREXIA-AF comparing milvexian 100 BID versus apixaban; LIBREXIA-STROKE comparing milvexian 25 BID versus placebo for recent non-AF stroke. The OCEANIC- STROKE study is comparing asundexian 50 daily versus placebo for recent non-AF stroke. The LIBREXIA-ACS study comparing milvexian 25 mg BID versus placebo for recent ACS was stopped in November 2025.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
16/LIBREXIA-AF (milvexian phase 3):

🔹For patients with AF or atrial flutter
A figure shows the LIBREXIA-AF study design where participants are randomly assigned to milvexian 100 mg or apixaban (5 mg or 2.5 mg per label indication) twice daily. Participants will be stratified by baseline planned use of any antiplatelet medication for at least 30 days. They are followed until the prespecified number of endpoint events is observed. At the end of treatment visit, clinicians may place participants on open label apixaban. Primary efficacy outcome is to evaluate if milvexian is non-inferior to apixaban for the prevention of stroke and systemic embolism. Principal safety objective is to evaluate if milvexian is superior to apixaban in reducing the endpoint of ISTH major bleeding and the composite endpoint of ISTH major and CRNM bleeding events. Additional inclusion criteria for LIBREXIA-AF are one or both of the following categories of risk: 1 or more of the following: age more than 75 years, history of stroke. Two or more of the following: age 65-74 years, hypertension, diabetes, vascular disease (CAD, MI, PAD), or congestive heart failure.
January 14, 2026 at 8:10 PM
med-iqcardiology.bsky.social
12/Results for OCEANIC-AF (asundexian phase 3):

🔹Terminated early—rate of stroke and SE were higher in asundexian arm vs apixaban arm
🔹ISTH major bleeding scores were lower in asundexian arm
A figure shows the OCEANIC-AF study design that included patients with AF who were given either asundexian at 50 mg daily or apixaban 5 mg twice daily. The efficacy outcome was prevention of stroke and systemic embolism. The safety outcome was major bleeding events. A bar graph shows the efficacy and safety results. Stroke or systemic embolism occurred in 1.3% of patients taking asundexian and in 0.4% of patients taking apixaban with an HR of 3.79 and a 95% CI of 2.46 to 5.83. Major bleeding occurred in 0.2% of patients taking asundexian and in 0.7% of patients taking apixaban with an HR of 0.32 and a 95% CI of 0.18 to 0.55.
January 14, 2026 at 8:10 PM
cureusmedical.bsky.social
This case shows argatroban as a lifesaving bridge and a cautious transition to apixaban, despite recent subdural hematoma. Would you anticoagulate, or hold, in this scenario?

Read more: www.cureus.com/articles/437...

#Cureus #Hematology #Neurology #MedEd #Anticoagulation #MedSky
January 11, 2026 at 9:50 AM
nephtimes.bsky.social
In adults with provoked VTE and enduring risk factors, 12 months of low-dose apixaban reduced recurrent clots with a low risk of major bleeding. #nephrology #nephsky #dialysis
www.docwirenews.com/post/apixaba...
Apixaban Safe and Effective for Provoked VTE | Docwire News
In provoked venous thromboembolism (VTE) with enduring risks, 12 months of low-dose apixaban cut recurrent VTE with minimal major bleeding.
www.docwirenews.com
January 9, 2026 at 5:04 PM
ajkd.bsky.social
Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis

bit.ly/44IMgkk
Time to Treatment Discontinuation among Apixaban Users and Time to Initiation of Oral Anticoagulation Among Matched Non-Users. Note: OAC – oral anticoagulant. Apixaban users (in red) had filled their first apixaban prescription within 30 days from their new diagnosis with atrial fibrillation. Continued use was present when a subsequent apixaban prescription was filled within no more than 7 days after the most recent supply was exhausted. If no refill occurred, 7 days were added to the most recent days’ supply. Apixaban use also ended when a prescription for a different OAC was filled. Non-users (in blue) of an oral anticoagulant within the same number of days from their new diagnosis with atrial fibrillation as their matched apixaban user were followed for any subsequent initiation of any oral anticoagulant.
January 5, 2026 at 5:00 PM
otskiff.bsky.social
Started triple therapy today 🙏

Already been on apixaban & aspirin for years, now adding clopi 💊

Feeling nervous but hopeful, praying for benefits, mild side effects and nothing scary 🤞🤍🙏

#LongCovid #PwME #POTS #MCAS #ChronicMigraine #TeamClots
Three boxes of medication stacked on a wooden surface: Aspirin 75 mg gastro-resistant tablets on top, Apixaban 5 mg film-coated tablets in the middle, and Clopidogrel 75 mg film-coated tablets at the bottom, indicating triple antithrombotic therapy.
January 5, 2026 at 3:26 PM
fimea.bsky.social
Apiksabaania käytetään veren hyytymisen estoon esim. verisuonitukosten yhteydessä. Nyt suurin osa valmisteista on poistunut markkinoilta. Apixaban används för att förebygga blodproppar t.ex. vid venösa tromboser. Nu har största delen av preparaten tagits bort från marknaden. fimea.fi/-/antikoagul...
Piirroskuva kahdesta lääkepurkista. Tecknad bild av två medicinburkar.
January 5, 2026 at 12:52 PM
calvin-r-wei.bsky.social
Patients with liver disease have complex hemostasis. Which blood thinner is safest?

We conducted a Network Meta-Analysis to compare Apixaban, Rivaroxaban, Dabigatran, and Warfarin.

doi.org/10.7759/cureus.72351

#WeiPublications #Hepatology #CardioSky #MedSky #LiverDisease #Cirrhosis #Afib #FOAMed
Comparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis
Atrial fibrillation (AF) patients with liver disease present unique challenges in anticoagulation management due to increased risks of both thromboembolism and bleeding. This network meta-analysis aim...
doi.org
January 3, 2026 at 10:21 PM
deniseannj.bsky.social
I share your concerns Louise. I'm on Apixaban and don't need a fall, which could have bad consequences. I brought the bins in earlier, there was white & black ice on the steps, so with -5degC forecast next couple of nights the ice isn't going anywhere fast, I'm probably housebound for a while yet.
January 3, 2026 at 3:41 PM
thehumanstrobe.bsky.social
I take apixaban and cloiodgrel, aspirin isnt the best for thinning blood either so not sure with his obsession with that
January 3, 2026 at 2:51 PM
chas0853.bsky.social
Yes. Could be on both. Standard protocol for folks his age with any evidence of heart disease could include BP meds, anticoagulants (eg., apixaban), and blood thinners.
January 2, 2026 at 10:13 PM
tropicalontour.bsky.social
Praise be for Apixaban.

Here’s to future August Bank Holiday fun that surpasses your previous high water mark. 🥂🍾
January 2, 2026 at 7:01 PM
quigonginnandjuice.bsky.social
Because I’m not a doctor I’m allowed to say shit like, “it seems like the president may be having frequent acute coronary events and strokes and his docs might want to try more aggressive therapies” but yes please consult a physician before starting warfarin or apixaban without discontinuing aspirin
January 1, 2026 at 4:33 PM
quigonginnandjuice.bsky.social
Not a doc but I know a bunch of cardiologists and it’s absolutely true that if you have extensive cardiac issues (like a history of heart attacks or strokes) that you do want “nice thin blood” and yes aspirin can help that but higher quantity ≠ better and you should add warfarin or apixaban
forbesmm.bsky.social Mike @forbesmm.bsky.social · 17d
banger of a quote
January 1, 2026 at 4:18 PM
thehumanstrobe.bsky.social
Blood thinners are used to thin blood and stop strokes and blood clots, i know because im on two of them.

I bet he's on apixaban.
ianboudreau.com Ian Boudreau @ianboudreau.com · 17d
Very smart sir, keep it up
January 1, 2026 at 3:00 PM
thecurbsiders.bsky.social
Choosing DOACs: Apixaban vs Rivaroxaban 💊 Choosing the right DOAC? Apixaban often leads the way! 🏆

🩺🔓 For more on this, listen to Curbsiders Patreon #60 Unlocked

www.patreon.com/curbsiders ⭐️
December 31, 2025 at 7:45 PM
rebel-em.bsky.social
🫀 Is Abelacimab the future of AFib anticoagulation?
🧬 Novel Factor XI inhibitor
📉 >60% less bleeding vs rivaroxaban
❓Stroke protection still uncertain
🔄 Needs Phase 3 trials vs apixaban
📖 Read more: https://wp.me/pdrP8b-5se
#FOAMed
December 26, 2025 at 1:05 PM
mrfrbussiness.bsky.social
Apixaban Market Size, Share Analysis, Trends, Report 2035 www.marketresearchfuture.com/reports/apix...
Apixaban Market Size, Share Analysis, Trends, Report 2035
Apixaban Market growth is projected to reach USD 14.45 Billion, at a 7.54% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast report 2025 to 2035
www.marketresearchfuture.com
December 26, 2025 at 7:40 AM
asaiojournal.bsky.social
Apixaban Anticoagulation in HeartMate 3 Left Ventricular Assist Device: A Meta-Analysis of Randomized Controlled Trials
ASAIO Journal 71(12):p e182-e183, December 2025. | DOI: 10.1097/MAT.0000000000002385
https://ow.ly/uNsk50XMI0C
#ASAIO
Meta-analysis of survival free from HRAEs for apixaban vs. warfarin in HeartMate 3 patients. CI, confidence interval; DOAC, direct oral anticoagulant; HRAE, hemocompatibility-related adverse event; LVAD, left ventricular assist device; RR, relative risk.
December 22, 2025 at 4:01 PM
trombosestichting.bsky.social
Sinds 18 december is Eliquis (apixaban) opnieuw leverbaar aan alle apotheken. Dit is mogelijk dankzij tijdelijke afspraken tussen groothandel Mosadex en fabrikant Bristol Myers Squibb.
December 22, 2025 at 11:18 AM
healthlawadamh.bsky.social
Interesting update re: the US Strategic Active Pharmaceutical Ingredient Reserve. #API💊
"Drugmakers promise to stockpile certain drugs as part of new drug pricing deals"
www.statnews.com/2025/12/19/d...
Screenshot of text from the linked article reading "But the stockpile is a new aspect. Some of the nine companies agreed to donate six months’ worth of certain drug ingredients to the Strategic Active Pharmaceutical Ingredient Reserve and to make finished-dose products from those ingredients during emergencies. Among them, Merck will supply the bulk ingredients for its antibiotic ertapenem; Bristol Myers Squibb will provide the blood thinner apixaban, commonly sold under the brand name Eliquis; and GSK will donate albuterol. Few details are available, including how many active pharmaceutical ingredients are being donated, their value, and whether companies are sending actual products to the government or maintaining their own reserves of ingredients. "
December 21, 2025 at 11:17 PM
jamacardiology.com
In this subanalysis of the ARTESiA RCT, apixaban increased the risk of major gastrointestinal bleeding compared to aspirin in patients with subclinical atrial fibrillation (SCAF), but fatal and intracranial bleeding rates were similar. ja.ma/4jaQtn1
JAMA Cardiology report: RCT comparing major bleeding with Apixaban vs Aspirin. Population: 2535 men, 1426 women. Intervention: 4012 patients randomized. Findings include hazard ratios for bleeding categories based on ISTH criteria.
December 20, 2025 at 12:00 PM
hematologyadvisor.bsky.social
Apixaban is safe and effective as VTE prophylaxis in obese pediatric patients with acute #lymphoblasticLeukemia and lymphoma. Published in @bloodjournals.hematology.org and @hematologyadvisor.bsky.social.

https://bit.ly/4rZ8N6J

#leusm #lymsm
Apixaban Safe, Effective as VTE Prophylaxis in Obese Pediatric Patients With ALL/LL - Oncology Nurse Advisor
Researchers sought to determine whether apixaban would be a safe and effective prophylactic treatment for VTE in obese pediatric patients with ALL/LL
bit.ly
December 18, 2025 at 11:34 PM